Differences in psychometric properties, cut-off scores, and outcomes between the Barthel Index and Modified Rankin Scale in pharmacotherapy-based stroke trials: systematic literature review

References

• Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269-76
   PubMed Web of Science ®Google Scholar
• American Stroke Association, Statistics 2006. Available at http://www.americanheart.org/downloadable/heart/1140534985281Statsupdate06book.pdf [Last accessed 10 December 2008]
   Google Scholar
• Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. Maryland State Med J 1965;14:61-5
   PubMedGoogle Scholar
• Collin C, Wade D. The Barthel Index: a reliability study. Int Disabil Stud 1988;10:61-3
   PubMedGoogle Scholar
• Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scot Med J 1957;2:200-15
   PubMedGoogle Scholar
• van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7
   PubMed Web of Science ®Google Scholar
• Kwon S, Hartzema AG, Duncan PW, et al. Disability measures in stroke. Relationship among the Barthel Index, the Functional Independence Measure, and the Modified Rankin Scale. Stroke 2004;35:918-23
   PubMed Web of Science ®Google Scholar
• Dromerick AW, Edwards DF, Diringer MN. Sensitivity to changes in disability after stroke: a comparison of four scales useful in clinical trials. J Rehabil Res Dev 2003;40:1-8
   PubMed Web of Science ®Google Scholar
• Weimar C, Kurth T, Kraywinkel K, et al. Assessment of functioning and stability after ischemic stroke. Stroke 2002;33:2053-9
   PubMed Web of Science ®Google Scholar
• Wolfe CDA, Taub NA, Woodrow EJ, et al. Assessment of scales of disability and handicap for stroke patients. Stroke 1991;22:1242-4
   PubMed Web of Science ®Google Scholar
• Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials. A systematic review and some recommendations to improve practice. Stroke 2000;31:1429-38
   PubMed Web of Science ®Google Scholar
• Gosman-Hedstrom G, Svensson E. Parallel reliability of the functional independence measure and the Barthel ADL index. Disabil Rehabil. 2000;22:702-15
   PubMed Web of Science ®Google Scholar
• Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019-26
   PubMed Web of Science ®Google Scholar
• Feigin VL, Doronin BM, Popova TF, et al. Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol. 2001;8:81-5
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, et al. for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25
   Google Scholar
• Diener HC. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. Cerebrovasc Dis. 1998;8:172-81
   PubMed Web of Science ®Google Scholar
• Franke CL, Palm R, Dalby M, et al. Flunarizine in stroke treatment (FIST): a double-blind, placebo-controlled trial in Scandinavia and the Netherlands. Acta Neurol Scand 1996;93:56-60
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study GroupTissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-7
   PubMed Web of Science ®Google Scholar
• Steiner T, Bluhmki E, Kaste M, et al. for the ECASS Study Group. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. Cerebrovasc Dis. 1998;8:198-203
   Google Scholar
• Lyden P, Shuaib A, Ng K, et al. on behalf of the CLASS-I/H/T InvestigatorsClomethiazole acute stroke study in ischemic stroke (CLASS-I). Stroke. 2002;33:122-8
   Google Scholar
• Lees KR, Zivin JA, Ashwood T, et al. for the Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Eng J Med. 2006;354:588-600
   Google Scholar
• Hacke W, Albers G, Al-Rawi Y, et al. for the DIAS Study Group. The desmoteplase in acute ischemic stroke trial (DIAS). A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73
   PubMed Web of Science ®Google Scholar
• The Abiciximab in Ischemic Stroke InvestigatorsAbciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000;31:601-9
   Google Scholar
• Clark WM, Albers GW, Madden KP, Hamilton S, for the Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators. The rtPA (Alteplase) 0- to 6-hour acute stroke trial, part A (A0276g). Stroke. 2000;31:811-6
   Google Scholar
• Lees KR, Dyker AG, Sharma A, et al. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients. A dose-ranging study. Stroke 2001;32:466-72
   PubMed Web of Science ®Google Scholar
• Lewandowski CA, Frankel M, Tomsick TA, et al. and the EMS Bridging Trial Investigators. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30:2598-605
   Google Scholar
• Diener HC, Cortens M, Ford G, et al. on behalf of the LUB-INT-13 Investigators. Lubeluzole in acute ischemic stroke treatment. A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke. 2000;31:2543-51
   Google Scholar
• Kwiatkowski TG, Libman RB, Frankel M, et al. for the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Eng J Med. 1999;340:1781-7
   Google Scholar
• Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke. Results of the Enlimomab acute stroke trial. Neurology 2001;57:1428-34
   PubMed Web of Science ®Google Scholar
• Ogawa A, Mori E, Minematsu K, et al. For The MELT Japan Study Group. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan. Stroke. 2007;38:2633-9
   Google Scholar
• Diener H-C, Sacco RL, Yusuf S, et al. For the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875-84
   Google Scholar
• Chao AC, Teng MM, Chung CP, et al. Preliminary efficacy report of a novel thrombolytic agent for acute ischaemic stroke within a 5-hour window. CNS Drugs 2007;21:937-46
   PubMed Web of Science ®Google Scholar
• Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007;69:1404-10
   PubMed Web of Science ®Google Scholar
• Nader-Kawachi J, Gongora-Rivera F, Santos-Zambrano J, et al. Neuroprotective effect of dapsone in patients with acute ischemic stroke: a pilot study. Neurol Res 2007;29:331-4
   PubMed Web of Science ®Google Scholar
• Lyden PD, Shuaib A, Lees KR, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT trial. Stroke 2007;38:2262-9
   PubMed Web of Science ®Google Scholar
• Granger CV, Devis LS, Peters MC, et al. Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil. 1979;60:14-17
   PubMed Web of Science ®Google Scholar
• Kay R, Wong KS, Perez G, et al. Dichotomizing stroke outcomes based on self-reported dependency. Neurology 1997;49:1694-6
   PubMed Web of Science ®Google Scholar
• Uyttenboogaart M, Stewart RE, Vroomen PCAJ, et al. Optimizing cutoff scores for the Barthel index and the modified Rankin scale for defining outcome in acute stroke trials. Stroke 2005;36:1984-7
   PubMed Web of Science ®Google Scholar
• Celani MG, Cantisani TA, Righetti E, et al. on behalf of the Italian International Stroke Trial (IST) Collaborators. Different measures for assessing stroke outcome. An analysis from the International Stroke Trial in Italy. Stroke 2002;33:218-23
   PubMed Web of Science ®Google Scholar
• Sulter G, Steen C, Keyser JD. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999;30:1538-41
   PubMed Web of Science ®Google Scholar
• Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004;61:1066-70
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Juniper EF, Walter SD, et al. Interpreting treatment effects in randomised trials. BMJ 1998;316:690-3
   PubMed Web of Science ®Google Scholar
• Walter SD. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med 2001;20:3947-62
   PubMed Web of Science ®Google Scholar
• Young FB, Lees KR, Weir CJ, for the Glycine Antagonist in Neuroprotection (GAIN) International Trial Steering Committee and Investigators. Strengthening acute stroke trials through optimal use of disability end points. Stroke 2003;34:2676-80
   Google Scholar
• Lees KR. Neuroprotection is unlikely to be effective in humans suing current trial designs: an opposing view. Stroke 2002;33:308-9
   PubMed Web of Science ®Google Scholar
• Berge E, Barer D. Could stroke trials be missing important treatment effects? Cerebrovasc Dis 2002;13:73-5
   PubMed Web of Science ®Google Scholar
• Tilley BC, Marler J, Geller NL, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke 1996;27:2136-42
   PubMed Web of Science ®Google Scholar
• Weir CJ, Kaste M, Lees KR, for the Glycine Antagonist in Neuroprotection (GAIN) International Trial Steering Committee and Investigators. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy. Stroke. 2004;35:2111-16
   PubMedGoogle Scholar
• New PW, Buchbinder R. Critical appraisal and review of the Rankin scale and its derivatives. Neuroepidemiology 2006;26:4-15
   PubMed Web of Science ®Google Scholar
• Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603-12
   PubMed Web of Science ®Google Scholar